Press "Enter" to skip to content

New patent for Novartis drug TASIGNA

0
Copyright © DrugPatentWatch. Originally published at New patent for Novartis drug TASIGNA

Annual Drug Patent Expirations for TASIGNA
Annual Drug Patent Expirations for TASIGNA

Tasigna is a drug marketed by Novartis
and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and forty-one patent family members in fifty countries.

The generic ingredient in TASIGNA is nilotinib hydrochloride monohydrate. One supplier is listed for this compound. Additional details are available on the nilotinib hydrochloride monohydrate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Summary
New patent for Novartis drug TASIGNA
Article Name
New patent for Novartis drug TASIGNA
Description
Tasigna is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.
Author
Publisher Name
DrugPatentWatch
Copyright © DrugPatentWatch. Originally published at New patent for Novartis drug TASIGNA
Do NOT follow this link or you will be banned from the site!